PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

FDA's John Whyte Delves Deeper into Patient Centricity

iDSI: Making NICE in Low and Middle Income Countries

The State of Market Insights in Pharma
Regulatory Affairs
Biosimilars Gaining Traction as Regulator Confidence Grows
Biosimilars are gaining more support among payers and physicians, but more needs to be done to explain their benefits as well as their safety and efficacy profiles, writes Barbara Testa.
... /Read more/
Advertisement
Read this Front & Center article to see how your Hub can be a Secret Weapon to improve Outcomes. Learn more
Pricing
The Innovation Gap in Executive Compensation
How the need for biopharma innovation extends to questions around executive compensation. By Carl Sjostrom and Ian Wilcox.
... /Read more/
Technology
Exponential Medicine and Pharma's Unfulfilled Promise
Bill Drummy reviews the "techno-optimistic" highlights of this year's Exponential Medicine conference in San Diego.
... /Read more/
Strategy
Pharma Must Embrace Digital Transformation
However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities — if only to ward off disruption, says Elvis Pacelat.
... /Read more/
Calendar
 
/ 12th Life Sciences Trade and Channel Strategies /
 
/ PCC 2017 - CBI's 14th Annual Pharmaceutical Compliance Congress /
 
Regulatory Affairs
Something for Everyone in "Cures" Package
Congress's enactment of 21st Century Cures legislation may have given pharmaceutical manufacturers an early Christmas present, but some concerns are being voiced, writes Jill Wechsler.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com